MEVE 019: Unit 15 - Multidrug-Resistant Organisms
UNIT 15: MULTIDRUG-RESISTANT ORGANISMS
15.1
Introduction
Antimicrobial
resistance (AMR) is one of the most pressing global health challenges of the
21st century. When bacteria, viruses, fungi, or parasites evolve to resist the
drugs that once killed them, they become multidrug-resistant organisms (MDROs). These
organisms make infections harder to treat and increase the risk of disease
spread, severe illness, and death. The rise of MDROs threatens to undo decades
of medical progress, making once-curable infections deadly again.
15.2
Objectives
By the end of
this unit, learners will be able to:
·
Define multidrug-resistant organisms (MDROs).
·
Understand the causes and extent of antimicrobial resistance.
·
Explore emerging infectious diseases linked to drug resistance.
·
Learn about mechanisms through which resistance develops.
·
Assess the health and economic impacts of MDROs.
·
Recognize global and national management strategies and policies.
15.3
Definition
Multidrug-resistant
organisms (MDROs) are microorganisms that have developed resistance to multiple
antibiotics or antimicrobial agents, rendering standard treatments ineffective.
These organisms can include:
·
Bacteria (e.g., MRSA – Methicillin-resistant Staphylococcus aureus)
·
Viruses (e.g., drug-resistant HIV)
·
Fungi (e.g., Candida auris)
·
Parasites (e.g., drug-resistant Plasmodium falciparum in malaria)
They are
often referred to as "superbugs" in public discourse.
15.4
Causes of Antimicrobial Resistance
The
development of resistance is a natural evolutionary process, but human activities
have accelerated
it:
1. Overuse and
Misuse of Antibiotics:
o Prescribing
antibiotics for viral infections.
o Over-the-counter
availability of antibiotics in some countries.
o Incomplete
dosage or unnecessary usage.
2. Agricultural
Use:
o Antibiotics
used in livestock for growth promotion and disease prevention.
3. Poor
Infection Control:
o Inadequate
hygiene and sanitation in hospitals and communities.
4. Lack of New
Antibiotics:
o Few new
antibiotics are being developed due to high costs and low returns.
5. Global Travel
and Trade:
o Resistant
microbes can quickly spread from one region to another.
15.5
Extent
·
Global Spread: AMR is a problem in every region of the world.
·
India: One of the highest rates of antibiotic use and resistance.
·
WHO Statistics: By 2050, AMR could cause 10 million deaths per year, surpassing cancer.
·
Examples of Resistant Organisms:
o Carbapenem-resistant
Klebsiella
pneumoniae
o Multidrug-resistant
Mycobacterium
tuberculosis (MDR-TB)
o Extensively
drug-resistant Neisseria
gonorrhoeae
15.6
Emerging Infectious Diseases
Drug
resistance also affects new and emerging infections:
·
Tuberculosis (TB): MDR-TB and XDR-TB (Extensively drug-resistant TB) are growing
threats.
·
HIV/AIDS: Resistance to first-line antiretroviral drugs is rising.
·
Malaria: Resistance to artemisinin has been reported in parts of Asia and
Africa.
·
COVID-19: Secondary infections during the pandemic raised concerns about
antibiotic misuse.
15.7
Mechanism
Antimicrobial
resistance occurs through various biological mechanisms:
1. Genetic
Mutation: Spontaneous changes in microbial DNA that reduce drug
effectiveness.
2. Gene
Transfer: Resistant genes can be transferred between microbes through
plasmids.
3. Drug
Inactivation: Some bacteria produce enzymes that deactivate antibiotics (e.g.,
β-lactamase).
4. Efflux Pumps: Some
microbes pump out the drug before it can act.
5. Target
Modification: The drug’s target in the microbe is altered, rendering it
ineffective.
6. Biofilm
Formation: Communities of microbes protect themselves within biofilms.
15.8
Impacts
Health
Impacts:
·
Increased morbidity and mortality due to untreatable
infections.
·
Longer hospital stays and frequent treatment failures.
·
Reduced effectiveness of major medical procedures (e.g.,
surgeries, chemotherapy).
Economic
Impacts:
·
Higher healthcare costs for treatment and extended care.
·
Loss of productivity due to prolonged illness.
·
Burden on national health systems.
Societal
Impacts:
·
Fear of infection spreads in communities.
·
Rise of stigmatization in high-risk patients (e.g., TB, HIV).
·
Loss of trust in healthcare systems.
15.9
Management and Policy
Global
Strategies:
·
WHO Global Action Plan (GAP) on AMR: Focus on
surveillance, education, and research.
·
Global Antimicrobial Resistance Surveillance System (GLASS): Monitoring
of resistance data.
National
Action in India:
·
National Action Plan on AMR (2017–2021): Aims to
reduce misuse, improve surveillance, and promote research.
·
Red Line Campaign: Marking prescription-only antibiotics with a red line to
discourage misuse.
·
ICMR (Indian Council of Medical Research): Conducts
AMR surveillance in hospitals.
Hospital
and Community-Level Actions:
·
Antibiotic Stewardship Programs (ASP): Monitoring
and regulating antibiotic use.
·
Infection Prevention and Control (IPC): Hand
hygiene, disinfection, isolation wards.
·
Public Awareness Campaigns: Educating people about correct
antibiotic use.
Policy
Recommendations:
·
Strengthen regulatory frameworks for antibiotic sales.
·
Ban non-therapeutic use in agriculture.
·
Invest in R&D for new antibiotics and vaccines.
·
Encourage international collaboration.
15.10
Let Us Sum Up
Multidrug-resistant
organisms (MDROs) represent a serious global health threat. Misuse of
antibiotics in humans and animals, lack of new drugs, and inadequate infection
control have accelerated the problem. The rise in resistant infections has
health, economic, and social consequences. Combating AMR requires a multi-sectoral
approach involving governments, healthcare providers,
researchers, industries, and the public. Only through coordinated efforts can
we preserve the efficacy of life-saving antibiotics for future generations.
Comments
Post a Comment